Illumina has signed deals to genotype the sample collections at four biobanks. Each of the projects is aiming to build a repository of linked genotypic and phenotypic data, with the sequencing results generated by Illumina being paired to electronic medical records (EMRs) possessed by the owners of the biobanks.
In this week's Dx Digest, Illumina inked four biobanking deals to spur genetic research, liquid biopsy player Trovagene nabbed a coverage agreement for its cancer diagnostics, and diagnostics heavyweight Qiagen joined forces with genomics firm CosmosID to launch a metagenomics and microbiome analysis tool.
Illumina is off to a racing start in 2016, and the pace isn't showing any signs of slowing. The company is snatching up Conexio Genomics to get its hands on Conexio's transplant genotyping products, a couple of weeks after it unveiled its liquid biopsy spinoff and expanded genomics offerings.
Illumina has outlined its plan to release a semiconductor-based sequencing system. The product, currently dubbed Firefly, will become the first Illumina sequencing system to rely on something other than optical readouts.
Illumina revealed additions to its genomics portfolio at the annual J.P. Morgan Healthcare Conference and separately announced a deal with Bio-Rad Laboratories to develop a next-generation sequencing solution for single-cell analysis.
Illumina hasn't been shy about its liquid biopsy ambitions, with CEO Jay Flatley telling investors back in July that the company would focus on its work in the field to generate long-term growth. Now Illumina is taking things to the next level, launching a new company that's focused on developing a screening test for the early detection of cancer.
In this week's Dx Digest, Illumina struck a deal to expand its presence in China, Hologic snagged a CE mark for its test for a common but oft-misdiagnosed sexually transmitted infection, and diagnostics giant LabCorp snatched up medical testing unit Pathology to get its hands on the company's molecular and digital pathology services.
Illumina and bioMérieux have launched a whole genome sequencing service that's aimed at improving epidemiological monitoring and control of hospital-acquired infection.
Illumina has invested in Desktop Genetics (DTG), a developer of software to support CRISPR gene editing. The funding will go toward integrating DTG's tool into NGS pipelines, bringing the CRISPR software closer to the core of Illumina's business.
Illumina is to make a 5,000-genome autism database available through BaseSpace. The deal will enable researchers to analyze the genomes of people with autism and their families using tools built into Illumina's cloud computing platform.